Epitalon
A synthetic tetrapeptide (AEDG) developed as the defined-sequence counterpart to the pineal extract Epithalamin. It is the most widely discussed of the Khavinson bioregulators and carries the strongest claims — telomerase activation and lifespan extension — on some of the field's thinnest human evidence. Cell and rodent work is real and replicated in part; the longevity claims made for it in popular sources are not.
Ala-Glu-Asp-Gly · 4 residues · 390.35 Da (computed)
Contains no lysine.
Bioregulator context
Target tissue: pineal gland (endocrine)
That a short peptide corresponding to a regulatory motif of pineal origin can restore age-related decline in melatonin rhythm and, through sequence-specific interaction with DNA, normalise gene expression in the tissue it derives from.
Proposed to bind CpG-rich promoter regions directly, with the peptide's small size and charge allowing it to reach DNA and modulate transcription in a tissue-specific way. The binding model is largely structural and computational; it has not been demonstrated to drive the claimed physiological outcomes in humans.
Mechanism
Claimed
Activates telomerase, lengthens telomeres, restores pineal melatonin rhythm, and slows biological ageing.
Actually established
Telomerase upregulation and telomere lengthening have been observed in human cell lines in vitro. Nothing about ageing, melatonin rhythm, or lifespan in humans has been established.
How good is the evidence
The best-supported finding is in cell culture: telomerase upregulation and telomere lengthening in human cell lines, reported by an independent group in 2025. Animal work on oocyte ageing and wound healing exists. Human evidence for the headline longevity claims is essentially absent from the English-language indexed literature — what circulates as 'clinical trials' is largely Russian-language work from the originating institute that has not been independently replicated.
The in-vitro telomerase finding is notable precisely because it comes from a group unconnected to the compound's developers. Most other Epitalon literature originates from the St Petersburg Institute of Bioregulation and Gerontology, frequently with Khavinson as an author.
Claims, one at a time
Each claim carries its own evidence tier. A compound is never simply "well studied" — some of its claims may be, others not at all.
| Claim | Verdict | Evidence | Basis |
|---|---|---|---|
| Lengthens telomeres and activates telomerase | mixed | In vitro | Demonstrated in human cell lines in vitro by an independent group, via telomerase upregulation or ALT activity. No human in-vivo data shows the same effect, and telomere lengthening in culture does not establish any clinical benefit. |
| Extends human lifespan | untested | Anecdote | No controlled human lifespan study exists. This claim circulates via vendor marketing and secondary summaries of Russian cohort reports that have not been independently verified. |
| Protects ageing oocytes | supported | Animal | Reported in mouse oocytes in vitro under post-ovulatory ageing conditions. Species- and model-specific; no human relevance established. |
The studies themselves
| Study | Design | Subjects | Quality |
|---|---|---|---|
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
Al-Dulaimi S, et al. (4 authors, senior author Roberts T) · Biogerontology · 2025
PMID 40908429
|
in_vitro / cell_culture | — Human cell lines | In vitro
risk of bias: unclear
|
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro
See PubMed record (Aging, 2022) · Aging · 2022
PMID 35413689
|
animal_uncontrolled / mouse | — Mouse oocytes, post-ovulatory ageing model | Animal
risk of bias: unclear
|
Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties
Araj SK, et al. (4 authors, senior author Szeleszczuk Ł) · International Journal of Molecular Sciences · 2025
PMID 40141333
|
narrative_review / mixed | Mechanistic
risk of bias: unclear
|
- No human pharmacokinetic data exists — absorption, half-life, distribution and clearance are uncharacterised for any route in common use.
- Whether in-vitro telomerase upregulation translates to any effect in a living human is entirely untested.
- The Russian-language clinical literature frequently cited for this compound has not been read, translated, or independently assessed for this entry.
- No long-term safety data of any duration exists in humans.
- Whether the proposed direct DNA-binding mechanism operates at physiologically achievable concentrations is unresolved.
What people actually report
- debates over telomerase and sleep research
- personal reports about sleep and circadian effects
- concern about possible cancer risk
- questions about combining it with other peptides
- claims about longevity and biological aging
What people keep asking
- What does the research actually show about telomerase and sleep?
- What experiences have people had with Epitalon?
- Are concerns about cancer risk justified?
- How does Epitalon interact with other peptides or substances?